In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


All Hail Biopharma Market Performance

Executive Summary

The first half of the year after a presidential election has meant losses for biopharma indices in the last three election cycles. On the heels of a year of strong performance for the sector, can momentum hold into 2013?

You may also be interested in...

More And Better Biotech IPOs, But Step-Ups Still Lag

Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.

Stockwatch: The Pandemic – Where Generics Failed To Reign

If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.

QUOTED. 1 March 2021. Xavier Becerra.

California state Attorney General Xavier Becerra promised during two US Senate committee hearings that, if confirmed as Secretary of Health and Human Services, he will let science shape HHS policy.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts